Articles of manufacture and methods for treatment using adoptive cell therapy

Patent metadata

Field	Value
Publication number	US-11944647-B2
Application number	US-202217846868-A
Country	US
Kind code	B2
Filing date	Jun 22, 2022
Priority date	Jun 2, 2017
Publication date	Apr 2, 2024
Grant date	Apr 2, 2024

Abstract

Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.

First claim

The invention claimed is:

1. A method of treating a subject having small lymphocytic lymphoma (SLL), the method comprising administering to the subject a dose of T cells comprising T cells expressing a chimeric antigen receptor (CAR) that specifically binds to CD19, the dose of T cells comprising a ratio of CD 4+ cells expressing the CAR to CD 8+ cells expressing the CAR of between at or about 5:1 and at or about 1:5, wherein;
administering the dose of T cells comprises administering a plurality of separate compositions, the plurality of separate compositions comprising a first composition comprising one of the CD4+ T cells and the CD8+ T cells and a second composition comprising the other of the CD4+ T cells and the CD8+ T cells;
the subject has relapsed following remission after treatment with, or become refractory to, one or more prior therapies; and
the CAR comprises an scFv specific for CD19, a transmembrane domain, a cytoplasmic signaling domain derived from a costimulatory molecule, a cytoplasmic signaling domain that comprises a CD3zeta signaling domain, and a spacer between the transmembrane domain and the scFv.

2. The method of claim 1 , wherein the subject has relapsed following remission after treatment with, or become refractory to, two or more prior lines of therapy.

3. The method of claim 1 , wherein the subject has relapsed following remission after treatment with, or become refractory to, one prior therapy.

4. The method of claim 1 , wherein the dose of T cells comprises between at or about 5×10 7 CAR-expressing viable T cells and about 1.5×10 8 CAR-expressing viable T cells.

5. The method of claim 4 , wherein the ratio of CD 4+ cells expressing the CAR to CD 8+ cells expressing the CAR is about 1:1.

6. The method of claim 1 , wherein the dose of T cells comprises about 1×10 8 CAR-expressing viable T cells.

7. The method of claim 1 , wherein the costimulatory molecule is 4-1BB.

8. A method of treating a subject having chronic lymphocytic leukemia (CLL), the method comprising administering to the subject a dose of T cells comprising T cells expressing a chimeric antigen receptor (CAR) that specifically binds to CD19, the dose of T cells comprising a ratio of CD 4+ cells expressing the CAR to CD 8+ cells expressing the CAR of between at or about 5:1 and at or about 1:5, wherein:
administering the dose of T cells comprises administering a plurality of separate compositions, the plurality of separate compositions comprising a first composition comprising one of the CD4+ T cells and the CD8+ T cells and a second composition comprising the other of the CD4+ T cells and the CD8+ T cells;
the subject has relapsed following remission after treatment with, or become refractory to, one or more prior therapies; and
the CAR comprises an scFv specific for CD19, a transmembrane domain, a cytoplasmic signaling domain derived from a costimulatory molecule, a cytoplasmic signaling domain that comprises a CD3zeta signaling domain, and a spacer between the transmembrane domain and the scFv.

9. The method of claim 8 , wherein the subject has relapsed following remission after treatment with, or become refractory to, two or more prior lines of therapy.

10. The method of claim 8 , wherein the subject has relapsed following remission after treatment with, or become refractory to, one prior therapy.

11. The method of claim 8 , wherein the dose of T cells comprises between at or about 5×10 7 CAR-expressing viable T cells and about 1.5×10 8 CAR-expressing viable T cells.

12. The method of claim 11 , wherein the ratio of CD 4+ cells expressing the CAR to CD 8+ cells expressing the CAR is about 1:1.

13. The method of claim 8 , wherein the dose of T cells comprises about 1×10 8 CAR-expressing viable T cells.

14. A method of treating a subject having Mantle cell lymphoma (MCL), the method comprising administering to the subject a dose of T cells comprising T cells expressing a chimeric antigen receptor (CAR) that specifically binds to CD19, the dose of T cells comprising a ratio of CD 4+ cells expressing the CAR to CD 8+ cells expressing the CAR of between at or about 5:1 and at or about 1:5, wherein:
administering the dose of T cells comprises administering a plurality of separate compositions, the plurality of separate compositions comprising a first composition comprising one of the CD4+ T cells and the CD8+ T cells and a second composition comprising the other of the CD4+ T cells and the CD8+ T cells;
the subject has relapsed following remission after treatment with, or become refractory to, one or more prior therapies; and
the CAR comprises an scFv specific for CD19, a transmembrane domain, a cytoplasmic signaling domain derived from a costimulatory molecule, a cytoplasmic signaling domain that comprises a CD3zeta signaling domain, and a spacer between the transmembrane domain and the scFv.

15. The method of claim 14 , wherein the subject has relapsed following remission after treatment with, or become refractory to, two or more prior lines of therapy.

16. The method of claim 14 , wherein the subject has relapsed following remission after treatment with, or become refractory to, one prior therapy.

17. The method of claim 14 , wherein the dose of T cells comprises between at or about 5×10 7 CAR-expressing viable T cells and about 1.5×10 8 CAR-expressing viable T cells.

18. The method of claim 17 , wherein the ratio of CD 4+ cells expressing the CAR to CD 8+ cells expressing the CAR is about 1:1.

19. The method of claim 14 , wherein the dose of T cells comprises about 1×10 8 CAR-expressing viable T cells.

20. The method of claim 14 , wherein the costimulatory molecule is 4-1BB.

Assignees

• Juno Therapeutics Inc

Inventors

• Albertson Tina
• Christin Brian
• Garcia Jacob Randolph
• Ramsborg Christopher Glen
• Sutherland Claire L
• Weber Clinton
• Yost Rachel K
• Gilbert Mark J
• Li He

Classifications

• A61K40/4211

  CD19 or B4 · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/38

  characterised by the dose, timing or administration schedule · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title